Literature DB >> 9721015

Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects.

A Smolenski1, A M Burkhardt, M Eigenthaler, E Butt, S Gambaryan, S M Lohmann, U Walter.   

Abstract

NO and cGMP have emerged as important signal transduction mediators of the effects of certain hormones, inter-/intracellular signals, toxins and drugs. However, a major challenge is to define relevant criteria for determining which of the many NO and/or cGMP effects are dependent on cGMP-dependent protein kinases (cGKs). Important criteria include that: (1) the cell types/tissues investigated contain at least one form of cGK which is activated by the cGMP-elevating agent in the intact cell system; (2) specific activators/inhibitors of cGKs mimic/block the effects of cGMP-elevating agents in the intact cell system; and (3) the cGMP effect is absent or blunted in cGK-deficient systems, or can be reconstituted by the introduction of active cGKs. Previously, analysis of cGK activity in intact cells has been very difficult. However, the analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation by polyclonal antibodies and newly developed monoclonal antibodies, each of which specifically recognize different phosphorylation sites, allows the quantitative measurement of cGK activity in intact cells. With the use of these methods, the properties of certain cGK mutants, cGK activators (cGMP, 8-Br-cGMP, 8-pCPT-cGMP) as well as various "specific cGK inhibitors" (KT 5823, Rp-8Br-PET-cGMPS, Rp-8-pCPT-cGMPS, H8 and H89) were investigated. Although these "specific cGK inhibitors" have been widely used to establish or rule out functional roles of cGKs, very few studies have actually addressed the efficiency/specificity of such compounds in intact cells. Our results demonstrate that these inhibitors are useful tools only when used in combination with other experimental approaches and biochemical evidence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721015     DOI: 10.1007/pl00005234

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.

Authors:  Jun Kotera; Kennard A Grimes; Jackie D Corbin; Sharron H Francis
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

2.  Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468.

Authors:  R Saravani; F Karami-Tehrani; M Hashemi; M Aghaei; R Edalat
Journal:  Cell Prolif       Date:  2012-04-02       Impact factor: 6.831

3.  Myristoylation of cGMP-dependent protein kinase dictates isoform specificity for serotonin transporter regulation.

Authors:  Yuan-Wei Zhang; Gary Rudnick
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

4.  KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells.

Authors:  Sasha Beyer; Aparna Lakshmanan; Yu-Yu Liu; Xiaoli Zhang; Irene Wapnir; Albert Smolenski; Sissy Jhiang
Journal:  Endocrinology       Date:  2011-01-05       Impact factor: 4.736

5.  The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells.

Authors:  Stepan Gambaryan; Elke Butt; Anna Kobsar; Joerg Geiger; Natalia Rukoyatkina; Rimma Parnova; Viacheslav O Nikolaev; Ulrich Walter
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

6.  The mediation of platelet quiescence by NO-releasing polymers via cGMP-induced serine 239 phosphorylation of vasodilator-stimulated phosphoprotein.

Authors:  Terry C Major; Hitesh Handa; Elizabeth J Brisbois; Melissa M Reynolds; Gail M Annich; Mark E Meyerhoff; Robert H Bartlett
Journal:  Biomaterials       Date:  2013-07-29       Impact factor: 12.479

Review 7.  Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity.

Authors:  Terry C Major; Hitesh Handa; Gail M Annich; Robert H Bartlett
Journal:  J Biomater Appl       Date:  2014-06-16       Impact factor: 2.646

8.  Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes.

Authors:  A Riad; D Westermann; S Van Linthout; Z Mohr; S Uyulmaz; P M Becher; H Rütten; P Wohlfart; H Peters; H-P Schultheiss; C Tschöpe
Journal:  Diabetologia       Date:  2008-09-30       Impact factor: 10.122

9.  Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis.

Authors:  Wenpeng Cui; Hasiyeti Maimaitiyiming; Xinyu Qi; Heather Norman; Qi Zhou; Xiaojun Wang; Jian Fu; Shuxia Wang
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

10.  YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells.

Authors:  Ming-Shyan Chang; Wen-Sen Lee; Che-Ming Teng; Horng-Mo Lee; Joen-Rong Sheu; George Hsiao; Chien-Huang Lin
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.